List of Advair Hfa drug patents
Advair Hfa is owned by Glaxo Grp Ltd.
Advair Hfa contains Fluticasone Propionate; Salmeterol Xinafoate.
Advair Hfa has a total of 4 drug patents out of which 0 drug patents have expired.
Advair Hfa was authorised for market use on 08 June, 2006.
Advair Hfa is available in aerosol, metered;inhalation dosage forms.
The generics of Advair Hfa are possible to be released after 26 August, 2026.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7832351 | GLAXO GRP LTD | Actuation indicator for a dispensing device |
Jun, 2023
(10 days from now) | |
|
US7832351 (Pediatric) | GLAXO GRP LTD | Actuation indicator for a dispensing device |
Dec, 2023
(6 months from now) | |
| US7500444 | GLAXO GRP LTD | Actuation indicator for a dispensing device |
Feb, 2026
(2 years from now) | |
|
US7500444 (Pediatric) | GLAXO GRP LTD | Actuation indicator for a dispensing device |
Aug, 2026
(3 years from now) | |
Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient
Market Authorisation Date: 08 June, 2006
Treatment: NA
Dosage: AEROSOL, METERED;INHALATION
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic